Pfizer Inc (PFE)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	2,119,000	10,482,000	21,472,000	29,051,000	31,372,000	29,771,000	29,309,000	24,966,000	21,979,000	19,432,000	12,755,000	10,681,000	9,159,000	7,730,000	13,941,000	15,498,000	16,027,000	16,217,000	12,651,000	11,477,000
Total stockholders’ equity	US$ in thousands	89,014,000	96,934,000	99,019,000	100,970,000	95,661,000	92,631,000	87,208,000	82,424,000	77,201,000	75,691,000	70,042,000	68,620,000	63,238,000	65,259,000	64,336,000	65,026,000	63,143,000	65,103,000	59,568,000	58,806,000
ROE		2.38%	10.81%	21.68%	28.77%	32.79%	32.14%	33.61%	30.29%	28.47%	25.67%	18.21%	15.57%	14.48%	11.85%	21.67%	23.83%	25.38%	24.91%	21.24%	19.52%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $2,119,000K ÷ $89,014,000K
= 2.38%

Pfizer Inc.'s return on equity (ROE) fluctuated over the past eight quarters, ranging from a low of 2.38% in Q4 2023 to a high of 33.61% in Q2 2022. The trend generally indicates a decreasing ROE performance over the recent quarters, with the most significant drop observed between Q2 2022 and Q4 2023. While the company experienced a strong ROE above 30% in the first half of 2022, the metric has since declined steadily. Investors may want to further investigate the factors contributing to this decline to assess Pfizer's financial performance and sustainability of its return on equity.